BridgeBio Pharma’s License Agreement with Bristol Myers Squibb

Goodwin Procter advised BridgeBio Pharma, Inc. on the deal.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. 

BridgeBio is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.

BBP-398 is a SHP2 inhibitor that is being developed for difficult-to-treat cancers and was founded through a collaboration with The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division.

Under the terms of the license agreement, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. BridgeBio will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities.

The Goodwin team advising BridgeBio on the license agreement was led by Noelle Dubiansky (Picture), and included Emily Beman, Adam Bellack, Alexandra Haas, Robby Frederickson, Can Cui, Steve Tjoe, Sarah Wicks, Dan Karelitz, Felix Krueger, Paul Jin, and Federica De Santis.

 

Involved fees earner: Adam Bellack – Goodwin Procter; Emily Beman – Goodwin Procter; Can Cui – Goodwin Procter; Federica De Santis – Goodwin Procter; Noelle Dubiansky – Goodwin Procter; Robert Frederickson – Goodwin Procter; Alexandra Haas – Goodwin Procter; Paul Jin – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Felix Krueger – Goodwin Procter; Steven Tjoe – Goodwin Procter; Sarah Wicks – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: BridgeBio Pharma LLC;

Martina Bellini

Author: Martina Bellini